Further to the information provided below, the sponsor of Anginine and Lycinate tablets, Arrow Pharmaceuticals, has advised the TGA that shortages of these products are expected to continue until September 2019.
The TGA has granted approval to Pfizer Australia to supply Nitrostat 600 mcg (0.6 mg) and 300 mcg (0.3 mg) tablets sourced from the United States of America under section 19A of the Therapeutic Goods Act 1989.
Consumers and health professionals are advised that the below mentioned unapproved product, GTN 300 mcg tablets sponsored by HL Pharma is no longer available under section 19A of the Therapeutic Goods Act 1989.
If you are a consumer and have any questions or concerns about this issue, talk to your health professional.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
